Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography

Brain Research

Volumn 631, Issue 2, 1993, Pages 191-202

  Schotte, A ^a   Janssen, P F M ^a   Megens, A A H P ^a   Leysen, J E ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

5 HT2 receptor; Clozapine; Dopamine D2 receptor; Haloperidol; Risperidone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; GUINEA PIG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

ANIMAL; ANTIPSYCHOTIC AGENTS; APOMORPHINE; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; CLOZAPINE; GUINEA PIGS; HALOPERIDOL; IN VITRO; IODINE RADIOISOTOPES; ISOXAZOLES; MALE; MESCALINE; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN; RISPERIDONE; STEREOTYPED BEHAVIOR;

EID: 0027743268     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(93)91535-Z     Document Type: Article

References (40)

1. Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy
2. 2-adrenergic receptors
3. 2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double blind with orphenadrine and placebo
4. Risperidone clinical safety and efficacy in schizophrenia
5. 125]iodosulpride
6. 3H]idazoxan
7. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of schizophrenic patients
8. Biochemical and behavioural properties of clozapine
9. The nucleus accumbens — possible site of antipsychotic action of neuroleptic drugs?
10. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side-effects
11. Maximum likelihood estimation
12. Pilot clinical investigation of risperidone in the treatment of psychotic patients
13. Adverse effects of clozapine
14. The effect of serotonergic agents on haloperidol-induced catalepsy
15. 2 antagonistic properties
16. 1 antagonist, Astemizole
17. Biochemical profile of risperidone, a new antipsychotic
18. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone
19. Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol
20. Interaction of haloperidol and risperidone (R 64766) with amphetamine-induced motility changes in rats
21. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79598)
22. Effects of antipsychotic drugs on serotonin receptors
23. i values
24. 1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates
25. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors
26. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors
27. Quantitative densitometry of neurotransmitter receptors
28. Thymostenic effects of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker
29. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects
30. 2 antagonists modulates the effects of D-2 dopamine receptor blockade
31. 125I]7-amino-8-iodo-ketanserin
32. Receptor occupancy by ritanserin and risperidone measured using ex vivo autodiography
33. Brain dopamine receptors
34. An anatomy of schizophrenia?
35. 2 antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition
36. 4 receptor with high affinity for the antipsychotic clozapine
37. Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and to clozapine